Pantoprazole Sodium for Injection Receives FDA Approval for Marketing Authorization
April 27, 2026
Source: drugdu
27
On April 24, *ST Shuangcheng(002693) issued an announcement stating that the company recently received a notification from the U.S. Food and Drug Administration (FDA) that its Abbreviated New Drug Application (ANDA) for Pantoprazole Sodium for Injection has been approved for marketing by the U.S. FDA. The drug is suitable for acute upper gastrointestinal bleeding such as duodenal ulcers, gastric ulcers, acute gastric mucosal lesions, and complex gastric ulcers.
This approval signifies that the company has reached the original research level in terms of safety and efficacy, demonstrating the company's R&D and production capabilities. It also enriches the company's international sales product pipeline and promotes the company's internationalization strategy.
In 2025, *ST Shuangcheng achieved revenue of 277 million yuan and net profit attributable to the parent company of 19.04 million yuan.
https://finance.eastmoney.com/a/202604243718365410.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- MicroWisdom Bio Completes Nearly RMB 100 Million B+ Round Supplementary Financing, Accelerating Bioartificial Liver Clinical Development and Industrialization April 27, 2026
- 【Exclusive】Cenglang BioTech Secures Tens of Millions in Financing, Strengthens Domestic Core Competitiveness, Accelerates Global Strategy April 27, 2026
- Largest Ever! India’s Sun Pharma to Acquire Organon for $11.75 Billion in All-Cash Deal, Reshaping the Global Pharmaceutical Landscape April 27, 2026
- Regeneron’s “world’s first” gene therapy for deafness approved for market launch. April 27, 2026
- Lunan Pharmaceutical Group’s miglitol raw material received approval from India’s DCGI April 27, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
